Aliases & Classifications for Drug Dependence

MalaCards integrated aliases for Drug Dependence:

Name: Drug Dependence 12 51 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9974
ICD9CM 34 304.6 304.60

Summaries for Drug Dependence

Disease Ontology : 12 A substance dependence that involves the continued use of drugs despite problems related to use of the substance.

MalaCards based summary : Drug Dependence is related to polysubstance abuse and hallucinogen dependence. An important gene associated with Drug Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Signaling by GPCR and Peptide ligand-binding receptors. The drugs Ethanol and Cocaine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Drug Dependence

Diseases related to Drug Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 polysubstance abuse 31.8 CNR1 DRD2 DRD3
2 hallucinogen dependence 31.1 CNR1 PENK
3 opiate dependence 30.2 DRD2 DRD3 OPRD1 OPRK1 OPRM1 PDYN
4 chronic pain 30.1 CNR1 OPRM1
5 cocaine dependence 30.1 CHRNB3 DRD2 DRD3 OPRD1 OPRK1 OPRM1
6 neonatal abstinence syndrome 30.0 OPRD1 OPRK1 OPRM1
7 substance dependence 29.9 BDNF CNR1 DRD2 DRD3 OPRD1 OPRK1
8 opioid abuse 29.8 DRD2 OPRM1 PDYN
9 antisocial personality disorder 29.6 ANKK1 DRD2 SLC6A4
10 social phobia 29.6 DRD2 SLC6A4
11 personality disorder 29.6 BDNF DRD2 DRD3 SLC6A4
12 obsessive-compulsive disorder 29.0 BDNF DRD2 DRD3 SLC6A4
13 bulimia nervosa 2 29.0 BDNF CRH POMC SLC6A4
14 withdrawal disorder 28.9 CNR1 CRH OPRM1 PDYN POMC
15 anxiety 28.9 BDNF CNR1 CRH OPRL1 SLC6A4
16 post-traumatic stress disorder 28.9 BDNF CNR1 CRH DRD2 SLC6A4
17 attention deficit-hyperactivity disorder 28.7 ANKK1 BDNF DRD2 DRD3 SLC6A4
18 tobacco addiction 28.3 ANKK1 CHRNA6 CHRNB3 DRD2 OPRM1
19 disease of mental health 27.6 BDNF CNR1 CRH DRD2 DRD3 OPRM1
20 alcohol dependence 25.9 ANKK1 BDNF CHRM2 CHRNA6 CNR1 DRD2
21 malaria 10.7
22 cannabis dependence 10.7
23 barbiturate dependence 10.7
24 alcohol use disorder 10.5 DRD2 SLC6A4
25 alcohol-induced mental disorder 10.5 DRD2 SLC6A4
26 atypical depressive disorder 10.4 CRH SLC6A4
27 cyclic vomiting syndrome 10.4 CNR1 OPRM1
28 morphine dependence 10.4 OPRD1 OPRK1 OPRM1
29 obsessive-compulsive personality disorder 10.4 DRD3 SLC6A4
30 delusional disorder 10.4 DRD2 DRD3
31 hypothalamic disease 10.4 CRH POMC
32 alexithymia 10.3 ANKK1 DRD2 SLC6A4
33 acth deficiency, isolated 10.3 CRH POMC
34 retrograde amnesia 10.3 PDYN POMC SLC6A4
35 pituitary carcinoma 10.3 CRH POMC
36 tardive dyskinesia 10.3 DRD2 DRD3
37 alcoholic psychosis 10.3 DRD2 SLC6A4
38 uremic pruritus 10.3 CNR1 OPRK1
39 pathological gambling 10.3 DRD2 DRD3 SLC6A4
40 opioid addiction 10.3 DRD2 OPRD1 OPRK1 OPRM1
41 impulse control disorder 10.3 ANKK1 DRD2 DRD3
42 nelson syndrome 10.3 CRH POMC
43 migraine without aura 10.3 DRD2 DRD3 SLC6A4
44 sheehan syndrome 10.2 CRH POMC
45 chronic fatigue syndrome 10.2 CRH POMC SLC6A4
46 hypoadrenalism 10.2 CRH POMC
47 generalized anxiety disorder 10.1 BDNF DRD2 SLC6A4
48 childhood disintegrative disease 10.1 BDNF POMC
49 postpartum depression 10.1 BDNF CRH SLC6A4
50 phobic disorder 10.0 OPRK1 SLC6A4

Graphical network of the top 20 diseases related to Drug Dependence:



Diseases related to Drug Dependence

Symptoms & Phenotypes for Drug Dependence

MGI Mouse Phenotypes related to Drug Dependence:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 OPRK1 PENK OPRL1 POMC OPRM1 SLC6A4
2 homeostasis/metabolism MP:0005376 10.2 PDYN PENK OPRK1 OPRL1 POMC OPRM1
3 growth/size/body region MP:0005378 10.11 PDYN PENK POMC OPRM1 SLC6A4 CRH
4 integument MP:0010771 10.07 OPRK1 PENK OPRL1 POMC OPRM1 SLC6A4
5 adipose tissue MP:0005375 10.02 PDYN POMC OPRM1 CRH DRD2 DRD3
6 endocrine/exocrine gland MP:0005379 10.01 OPRK1 PENK POMC OPRM1 SLC6A4 CRH
7 nervous system MP:0003631 10 OPRK1 OPRL1 POMC OPRM1 SLC6A4 PDYN
8 digestive/alimentary MP:0005381 9.98 PDYN OPRK1 OPRM1 BDNF DRD2 DRD3
9 no phenotypic analysis MP:0003012 9.61 PDYN PENK POMC OPRM1 OPRD1 CRH
10 normal MP:0002873 9.23 PENK OPRL1 OPRM1 SLC6A4 CNR1 CRH

Drugs & Therapeutics for Drug Dependence

Drugs for Drug Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 212)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1 64-17-5 702
2
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 446220 5760
3
Heroin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 561-27-3 5462328
4
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 89594 942
5
Naloxone Approved, Vet_approved Phase 4,Phase 2,Phase 1 465-65-6 5284596
6
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 537-46-2 10836
7
Methadone Approved Phase 4,Phase 2,Phase 3,Phase 1 76-99-3 4095
8
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 52485-79-7 644073 40400
9
Guaifenesin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 93-14-1 3516
10
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
11
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
12
Ribavirin Approved Phase 4 36791-04-5 37542
13
Dexmedetomidine Approved, Vet_approved Phase 4 76631-46-4, 113775-47-6 5311068 56032 68602
14
Oxytocin Approved, Vet_approved Phase 4,Phase 2 50-56-6 53477758 439302
15
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
16
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 16590-41-3 5360515
17
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
18
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
19 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
20 Respiratory System Agents Phase 4,Phase 2,Phase 3,Phase 1
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
22 Chlorpheniramine, phenylpropanolamine drug combination Phase 4,Phase 2,Phase 3,Phase 1
23 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Narcotic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
25 Narcotics Phase 4,Phase 3,Phase 2,Phase 1
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Analgesics, Non-Narcotic Phase 4
28 Analgesics, Opioid Phase 4,Phase 3,Phase 2,Phase 1
29 Nicotinic Agonists Phase 4,Phase 3,Phase 2,Phase 1
30 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Opiate Alkaloids Phase 4,Phase 2,Phase 3
32 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Buprenorphine, Naloxone Drug Combination Phase 4,Phase 2,Phase 1
34 Antitussive Agents Phase 4,Phase 2,Phase 3,Phase 1
35 interferons Phase 4
36 Adrenergic Agents Phase 4,Phase 2,Phase 3,Phase 1
37 Central Nervous System Stimulants Phase 4,Phase 2,Phase 3,Phase 1
38 Adrenergic Agonists Phase 4,Phase 2,Phase 3,Phase 1
39 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2,Phase 3,Phase 1
40 Adrenergic alpha-Agonists Phase 4,Phase 2,Phase 3,Phase 1
41 GABA Agents Phase 4,Phase 3,Phase 2
42 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Vasoconstrictor Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
45 Oxytocics Phase 4,Phase 2
46 Anesthetics, Local Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Hypnotics and Sedatives Phase 4,Phase 3,Phase 2
50 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 226)

# Name Status NCT ID Phase Drugs
1 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4 Buprenorphine
2 Treatment of Hepatitis C in Psychiatric Patients Completed NCT00751426 Phase 4
3 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
4 A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED) Completed NCT00605033 Phase 4 Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484;Subutex, Buprenorphine Hydrochloride, SCH 28444
5 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4 Suboxone (SCH 000484);Subutex (SCH 028444)
6 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4 Buprenorphine;Valproate
7 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4 Aripiprazole
8 Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation Completed NCT01070680 Phase 4 Precedex;sodium chlorid 0,9%
9 Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia Completed NCT02396979 Phase 4 Methadone
10 Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy Completed NCT01980550 Phase 4 sublingual nicotine
11 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
12 Buprenorphine and Integrated HIV Care Completed NCT00317460 Phase 4
13 Dexmedetomidine for Sepsis in ICU Randomized Evaluation Trial Completed NCT01760967 Phase 4 Dexmedetomidine
14 Buprenorphine and Methadone for Opioid Dependent Chronic Pain Patients Completed NCT00879996 Phase 4 Methadone;Buprenorphine/naloxone
15 The Whole Day First Grade Program Completed NCT00257088 Phase 4
16 A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users Recruiting NCT02192931 Phase 4 Creatine monohydrate
17 Effects of Intranasal Oxytocin on Cigarette Smoking Recruiting NCT02595749 Phase 4 Oxytocin;Placebo
18 Extended Release Naltrexone for Opioid-Dependent Youth Active, not recruiting NCT01843023 Phase 4 Extended Release Naltrexone;Buprenorphine
19 Oxytocin and Cognitive Behavioral Therapy in Drug Dependence Terminated NCT00975416 Phase 4 Intranasal Oxytocin;Placebo
20 Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial Terminated NCT00461890 Phase 4 Injectable Naltrexone
21 Anxiety in Recovering Opiate Dependence Terminated NCT00668265 Phase 4 Quetiapine
22 Buprenorphine as a Treatment in Opiate Dependent Pain Patients Terminated NCT00552578 Phase 4 buprenorphine/naloxone;buprenorphine/naloxone
23 Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents Withdrawn NCT01015066 Phase 4 Buprenorphine/naloxone;Naltrexone
24 Comparing Acute and Continuous Drug Abuse Treatment: A Randomized Clinical Trial Unknown status NCT01003496 Phase 3
25 Tobacco Intervention in Buprenorphine Treatment Unknown status NCT01350011 Phase 3
26 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
27 Job-Seekers Training for Patients With Drug Dependence - 1 Completed NCT00102362 Phase 3
28 Cocaine/Crack and Reduction of Compulsion With Biperiden Completed NCT01251393 Phase 3 Biperiden;Placebo
29 Making Alcoholics Anonymous Easier Completed NCT01382316 Phase 3
30 Prometa Pharmacotherapy for Methamphetamine Dependence Completed NCT00260481 Phase 2, Phase 3 Prometa;Placebo
31 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
32 Treating the Partners of Drug Using Pregnant Women: Stage II Completed NCT00496990 Phase 2, Phase 3
33 Addiction Health Evaluation And Disease Management (AHEAD) Study Completed NCT00278447 Phase 3
34 Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use Completed NCT00876941 Phase 3
35 Preventing Drug Use in Low Income Clinic Populations Completed NCT01942876 Phase 2, Phase 3
36 Sedative Premedication: Efficacy On Patient Experience Completed NCT01901003 Phase 3 Lorazepam;Placebo (microcrystalline celluloses)
37 Treating Tobacco Dependence in Adolescents With Co-occurring Psychiatric Disorders Completed NCT00618943 Phase 3
38 Efficacy of Topiramate for Hospitalized Patients With Alcoholism Completed NCT01145677 Phase 2, Phase 3 Topiramate
39 Directly Administered HIV Therapy in Methadone Clinics Completed NCT00279110 Phase 2, Phase 3
40 HIV/STD Safer Sex Skills Groups for Women in Drug Treatment Programs - 1 Completed NCT00084188 Phase 3
41 HIV/STD Safer Sex Skills Groups for Men in Drug Treatment Programs - 1 Completed NCT00084175 Phase 3
42 Improving Treatment Outcomes for Prescription Opioid Dependence Recruiting NCT02543944 Phase 2, Phase 3 Gabapentin;Buprenorphine;Clonidine;Naltrexone (oral);Naltrexone (depot);Placebo
43 The Role of Sleep in the Treatment of Cannabis Use Disorders Active, not recruiting NCT01685073 Phase 2, Phase 3 Zolpidem extended-release
44 Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day Active, not recruiting NCT03060083 Phase 2, Phase 3
45 Ketamine and Postoperative Cognitive Dysfunction Not yet recruiting NCT02892916 Phase 3 Ketamine;Placebo
46 Impact of Online Patient Feedback (OQ) to Therapist Unknown status NCT01891045 Phase 2
47 Sublingual Buprenorphine for Chronic Pain Unknown status NCT00612287 Phase 2 buprenorphine
48 Effectiveness of Extended Treatment for Drug Dependence (ETDD) in the City Study Completed NCT01153464 Phase 2
49 Memory Reconsolidation Blockade for Treating Drug Addiction Completed NCT01634347 Phase 2 Propranolol and memory reactivation;Placebo and memory reactivation
50 Social Cognition,Attentional Network and Nicotine Drug Dependency - A Pharmacological Clinical Trail Completed NCT00618280 Phase 1, Phase 2 nicotine nasal spray

Search NIH Clinical Center for Drug Dependence

Genetic Tests for Drug Dependence

Anatomical Context for Drug Dependence

MalaCards organs/tissues related to Drug Dependence:

38
Brain, Testes, Bone, Liver, Globus Pallidus, Prefrontal Cortex, Cortex

Publications for Drug Dependence

Articles related to Drug Dependence:

(show top 50) (show all 589)
# Title Authors Year
1
Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. ( 29439950 )
2018
2
Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells. ( 28038466 )
2017
3
Comparisons of Alcohol and Drug Dependence in Terms of Attachments and Clinical Issues. ( 28742416 )
2017
4
Acute pain management in patients with drug dependence syndrome. ( 29392226 )
2017
5
Prescribed drug dependence services for long-term BZD use: treating the problem while ignoring its causes. ( 29074682 )
2017
6
Association of the PLCB1 gene with drug dependence. ( 28860459 )
2017
7
Identifying Life-Threatening Admissions for Drug Dependence or Abuse (ILIADDA): Derivation and Validation of a Model. ( 28290530 )
2017
8
Patients with Infectious Endocarditis and Drug Dependence Have Worse Clinical Outcomes after Valvular Surgery. ( 28099093 )
2017
9
The relationship between fear extinction and resilience to drug-dependence in rats. ( 28322983 )
2017
10
Predictors of Inpatient Treatment Completion among Females with Opioid Use Disorder: Findings from a Tertiary Care Drug Dependence Treatment Centre of India. ( 28852241 )
2017
11
Pharmacovigilance in drugs used in the treatment of drug dependence. ( 29085108 )
2017
12
Association between severity of illicit drug dependence and quality of life in a psychosocial care center in BRAZIL: cross-sectional study. ( 29149893 )
2017
13
Hospitalizations for Endocarditis and Associated Health Care Costs Among Persons with Diagnosed Drug Dependence - North Carolina, 2010-2015. ( 28594786 )
2017
14
Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. ( 27046394 )
2016
15
Barriers in Access to the Treatment for People with Gambling Disorders. Are They Different from Those Experienced by People with Alcohol and/or Drug Dependence? ( 27832520 )
2016
16
Patterns of drug dependence in a Queensland (Australia) sample of Indigenous and non-Indigenous people who inject drugs. ( 27241554 )
2016
17
Illicit Drug Dependence ( 27227249 )
2016
18
Evidence for Association Between Low Frequency Variants in CHRNA6/CHRNB3 and Antisocial Drug Dependence. ( 27085880 )
2016
19
Does the choice of thrombotic prophylactic drug depend on the known risk factors of patients with multiple myeloma in clinical practice? ( 27208979 )
2016
20
A Retrospective Chart Review of Treatment Completers Versus Noncompleters Among In-patients at a Tertiary Care Drug Dependence Treatment Centre in India. ( 27570339 )
2016
21
Profile of female patients seeking in-patient treatment for prescription opioid abuse from a tertiary care drug dependence treatment centre from India. ( 26997020 )
2016
22
Distinct transcriptome profiles differentiate nonsteroidal anti-inflammatory drug-dependent from nonsteroidal anti-inflammatory drug-independent food-induced anaphylaxis. ( 26194548 )
2016
23
Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans. ( 27230395 )
2016
24
Barriers to community-based drug dependence treatment: implications for police roles, collaborations and performance indicators. ( 27435714 )
2016
25
Tryptophan for the sleeping disorder and mental symptom of new-type drug dependence: A randomized, double-blind, placebo-controlled trial. ( 27428201 )
2016
26
Ibogaine for treating drug dependence. What is a safe dose? ( 27426011 )
2016
27
Severe Psychosis, Drug Dependence, and Hepatitis C Related to Slamming Mephedrone. ( 27247820 )
2016
28
Mortality and illicit drug dependence among hemodialysis patients in the United States: a retrospective cohort analysis. ( 27278934 )
2016
29
Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. ( 26657151 )
2016
30
Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence. ( 27424166 )
2016
31
Abstinence From Drug Dependence After Bilateral Globus Pallidus Hypoxic-Ischemic Injury. ( 27311800 )
2016
32
Estimated probability of becoming a case of drug dependence in relation to duration of drug-taking experience: a functional analysis approach. ( 27356948 )
2016
33
Three Types of Adverse Childhood Experiences, and Alcohol and Drug Dependence Among Adults: An Investigation Using Population-Based Data. ( 27326749 )
2016
34
Stressful Events and Other Predictors of Remission from Drug Dependence in the United States: Longitudinal Results from a National Survey. ( 27776676 )
2016
35
Evidence of Shared Genome-Wide Additive Genetic Effects on Interpersonal Trauma Exposure and Generalized Vulnerability to Drug Dependence in a Population of Substance Users. ( 27214850 )
2016
36
Drug Dependence Treatment Awareness among Japanese Female Stimulant Drug Offenders. ( 27845738 )
2016
37
Association between DRD2/ANKK1 TaqIA polymorphism and common illicit drug dependence: evidence from a meta-analysis. ( 25500252 )
2015
38
Testing for drugs in exhaled breath collected with ExaBreathAr in a drug dependence population: comparison with data obtained in urine after LC-MS/MS analyses. ( 26222873 )
2015
39
Can psychedelic compounds play a part in drug dependence therapy? ( 25561484 )
2015
40
Patterns of Methylphenidate Use and Assessment of Its Abuse among the General Population and Individuals with Drug Dependence. ( 26491869 )
2015
41
Salutogenesis: Contextualising place and space in the policies and politics of recovery from drug dependence (UK). ( 26616849 )
2015
42
Negative mood reverses devaluation of goal-directed drug-seeking favouring an incentive learning account of drug dependence. ( 26041336 )
2015
43
[Role of intracellular Ca2+ dynamics in the development of drug dependence--Participation of Inositol 1,4,5-trisphosphate receptors]. ( 26255430 )
2015
44
Facilitating a transition from compulsory detention of people who use drugs towards voluntary community-based drug dependence treatment and support services in Asia. ( 26470779 )
2015
45
WHO Expert Committee on Drug Dependence. Thirty-sixth report. ( 26062388 )
2015
46
Association between experience of child abuse and severity of drug addiction measured by the Addiction Severity Index among Japanese drug-dependent patients. ( 25741639 )
2015
47
The Two Faces of Social Interaction Reward in Animal Models of Drug Dependence. ( 26088685 )
2015
48
Examining the role of common genetic variants on alcohol, tobacco, cannabis and illicit drug dependence: genetics of vulnerability to drug dependence. ( 25424661 )
2015
49
Stress and Drug Dependence Differentially Modulate Norepinephrine Signaling in Animals with Varied HPA Axis Function. ( 25601230 )
2015
50
Stigmatization of people with drug dependence in China: A community-based study in Hunan province. ( 24239068 )
2014

Variations for Drug Dependence

Expression for Drug Dependence

Search GEO for disease gene expression data for Drug Dependence.

Pathways for Drug Dependence

Pathways related to Drug Dependence according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.77 ACKR1 CHRM2 CNR1 CRH DRD2 DRD3
2
Show member pathways
12.77 ACKR1 CHRM2 CHRNA6 CHRNB3 CNR1 CRH
3
Show member pathways
11.7 BDNF DRD2 PDYN
4
Show member pathways
11.67 CHRM2 DRD2 DRD3
6 11.64 OPRD1 OPRM1 POMC
7
Show member pathways
11.55 CHRNA6 DRD2 DRD3
8 11.47 ACKR1 CHRM2 CNR1 DRD3
9 10.82 DRD2 DRD3
10 10.17 CRH POMC

GO Terms for Drug Dependence

Cellular components related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.91 CHRM2 CNR1 DRD2 DRD3 OPRD1 OPRK1
2 neuronal cell body GO:0043025 9.83 CHRM2 CRH OPRK1 PDYN PENK
3 axon GO:0030424 9.8 CNR1 DRD2 OPRM1 PENK
4 membrane raft GO:0045121 9.78 CNR1 OPRD1 OPRM1 SLC6A4
5 neuron projection GO:0043005 9.77 OPRD1 OPRK1 OPRL1 OPRM1 SLC6A4
6 postsynaptic membrane GO:0045211 9.76 CHRM2 CHRNA6 CHRNB3 OPRD1
7 dendrite GO:0030425 9.63 CHRM2 DRD2 OPRK1 OPRM1 PDYN PENK
8 dendrite membrane GO:0032590 9.52 OPRD1 OPRM1
9 acetylcholine-gated channel complex GO:0005892 9.51 CHRNA6 CHRNB3
10 symmetric synapse GO:0032280 9.4 CHRM2 PENK
11 perikaryon GO:0043204 9.35 CRH DRD2 OPRK1 OPRM1 PENK
12 axon terminus GO:0043679 9.1 CHRM2 DRD2 OPRD1 OPRK1 PDYN PENK
13 integral component of membrane GO:0016021 10.31 ACKR1 CHRM2 CHRNA6 CHRNB3 CNR1 DRD2
14 plasma membrane GO:0005886 10.17 ACKR1 CHRM2 CHRNA6 CHRNB3 CNR1 DRD2

Biological processes related to Drug Dependence according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 locomotory behavior GO:0007626 9.95 DRD2 DRD3 OPRK1 OPRM1 PENK
2 response to nicotine GO:0035094 9.91 CHRNA6 CHRNB3 CNR1 DRD2 PENK
3 sensory perception of pain GO:0019233 9.91 CNR1 OPRD1 OPRK1 OPRL1 OPRM1 PENK
4 response to ethanol GO:0045471 9.91 CNR1 CRH DRD2 DRD3 OPRK1 OPRM1
5 response to toxic substance GO:0009636 9.89 DRD2 PENK SLC6A4
6 response to estradiol GO:0032355 9.88 OPRL1 PENK SLC6A4
7 excitatory postsynaptic potential GO:0060079 9.88 CHRNA6 CHRNB3 DRD2 OPRM1
8 negative regulation of blood pressure GO:0045776 9.88 CNR1 CRH DRD2 DRD3 OPRL1
9 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.87 OPRD1 OPRK1 OPRL1 OPRM1
10 neuropeptide signaling pathway GO:0007218 9.87 OPRD1 OPRK1 OPRL1 OPRM1 PDYN PENK
11 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.86 CHRM2 CNR1 OPRD1 OPRM1
12 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.85 OPRD1 OPRK1 OPRM1
13 learning or memory GO:0007611 9.85 CNR1 CRH DRD3
14 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.84 CHRM2 CNR1 DRD2
15 regulation of sensory perception of pain GO:0051930 9.84 OPRD1 OPRK1 OPRL1 OPRM1
16 response to radiation GO:0009314 9.83 OPRK1 OPRM1 PENK
17 negative regulation of adenylate cyclase activity GO:0007194 9.83 DRD2 DRD3 OPRM1
18 eating behavior GO:0042755 9.83 OPRD1 OPRK1 OPRL1 OPRM1
19 synaptic transmission, cholinergic GO:0007271 9.8 CHRM2 CHRNA6 CHRNB3
20 opioid receptor signaling pathway GO:0038003 9.8 OPRD1 OPRK1 OPRL1 OPRM1
21 regulation of dopamine secretion GO:0014059 9.78 CHRNA6 DRD2 DRD3
22 behavioral response to cocaine GO:0048148 9.77 DRD2 DRD3 OPRK1
23 synaptic transmission, dopaminergic GO:0001963 9.77 CRH DRD2 DRD3
24 estrous cycle GO:0044849 9.75 OPRK1 OPRL1 OPRM1
25 dopamine receptor signaling pathway GO:0007212 9.72 DRD2 DRD3
26 negative regulation of protein secretion GO:0050709 9.72 DRD2 DRD3
27 negative regulation of cAMP biosynthetic process GO:0030818 9.72 OPRL1 OPRM1
28 startle response GO:0001964 9.72 DRD2 PENK
29 regulation of NMDA receptor activity GO:2000310 9.71 CRH OPRM1
30 behavioral response to ethanol GO:0048149 9.71 DRD2 OPRM1
31 dopamine metabolic process GO:0042417 9.71 DRD2 DRD3
32 negative regulation of voltage-gated calcium channel activity GO:1901386 9.7 DRD2 OPRL1
33 locomotory exploration behavior GO:0035641 9.7 CRH PENK
34 prepulse inhibition GO:0060134 9.7 DRD2 DRD3
35 positive regulation of renal sodium excretion GO:0035815 9.7 DRD2 DRD3
36 positive regulation of urine volume GO:0035810 9.69 DRD2 OPRL1
37 regulation of synaptic transmission, GABAergic GO:0032228 9.69 CNR1 DRD2
38 G-protein coupled receptor internalization GO:0002031 9.69 DRD2 DRD3
39 behavior GO:0007610 9.68 OPRK1 OPRL1
40 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.68 DRD2 DRD3
41 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.68 DRD3 OPRM1
42 regulation of cAMP metabolic process GO:0030814 9.67 DRD2 DRD3
43 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.66 DRD2 DRD3
44 positive regulation of behavioral fear response GO:2000987 9.66 CRH PENK
45 negative regulation of dopamine secretion GO:0033602 9.65 CNR1 DRD2
46 sensory perception GO:0007600 9.65 OPRK1 OPRL1 OPRM1 PDYN PENK
47 negative regulation of luteinizing hormone secretion GO:0033685 9.64 CRH OPRK1
48 negative regulation of dopamine receptor signaling pathway GO:0060160 9.64 DRD2 DRD3
49 acid secretion GO:0046717 9.63 DRD2 DRD3
50 response to histamine GO:0034776 9.63 DRD2 DRD3

Molecular functions related to Drug Dependence according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.85 CNR1 DRD2 DRD3 OPRD1 OPRL1 OPRM1
2 G-protein coupled receptor activity GO:0004930 9.81 ACKR1 CHRM2 CNR1 DRD2 DRD3 OPRD1
3 drug binding GO:0008144 9.62 CHRM2 CNR1 DRD2 DRD3
4 neuropeptide hormone activity GO:0005184 9.56 CRH PDYN PENK POMC
5 acetylcholine binding GO:0042166 9.52 CHRNA6 CHRNB3
6 acetylcholine-gated cation-selective channel activity GO:0022848 9.51 CHRNA6 CHRNB3
7 dopamine binding GO:0035240 9.49 DRD2 DRD3
8 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.48 DRD2 DRD3
9 dopamine neurotransmitter receptor activity GO:0004952 9.46 DRD2 DRD3
10 opioid receptor binding GO:0031628 9.43 PDYN PENK
11 opioid peptide activity GO:0001515 9.4 PDYN PENK
12 neuropeptide binding GO:0042923 9.26 OPRD1 OPRK1 OPRL1 OPRM1
13 opioid receptor activity GO:0004985 8.92 OPRD1 OPRK1 OPRL1 OPRM1

Sources for Drug Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....